Johnson & Johnson obtained FDA approval to market Simponi, or golimumab, as a treatment for moderate to severe forms of ulcerative colitis in adults. The drug, a tumor necrosis factor inhibitor previously approved for rheumatoid arthritis, is manufactured by J&J unit Janssen Biotech.
FDA expands use of Simponi to include ulcerative colitis
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||